In this study, we determined whether genetic variations in the IFN-γ/IFNGRs/JAKs/STATs/PD-L1 pathway were associated with prognosis of late-stage CRC patients receiving bevacizumab-based chemotherapy. The gene discussed is IFNG; the disease is colorectal carcinoma.